Table 6.
Generic name, year of approval | Trade name(s) | Dose | DEA schedule |
---|---|---|---|
Pancreatic lipase inhibitor approved by the FDA for long-term use (≥12 months) | |||
Orlistat, 1999 | Xenical | 120 mg 3 times daily before meals | Not scheduled |
Orlistat, 2007 | Alli (over the counter) | 60 mg 3 times daily before meals | Not scheduled |
Serotinin-2C receptor agonist approved by the FDA for long-term use (12 months) | |||
Lorcaserin, 2012 | Belviq | 10 mg twice daily | IV |
Combination of phentermine-topiramate approved by the FDA for long-term use (12 months) | |||
Phentermine-topiramate, 2012 | Qsymia | 3.75/23 mg 7.5/46 mg 15/92 mg |
IV |
Noradrenergic drugs approved for short-term use (usually <12 weeks) | |||
Diethylpropion, 1959 | Tenuate | 25 mg 3 times a day | IV |
Tenuate Dospan | 75 mg every morning | ||
Phentermine, 1959 | Adipex and many others | 15–30 mg/day | IV |
Benzphetamine, 1960 | Didrex | 25–50 mg 3 times daily | III |
Phendimetrazine, 1959 | Bontril | 17.5–70 mg 3 times daily | III |
Prelu-2 | 105 mg daily |
DEA, U.S. Drug Enforcement Administration; FDA, U.S. Food and Drug Administration.
Side effect profiles can be found in the package inserts for each agent.